Ultragenyx CLO sells 1,900 shares in planned trade

Ultragenyx Pharmaceutical Inc. EVP and Chief Legal Officer Karah Herdman Parschauer reported a sale of 1,900 shares of common stock on August 3, 2026 at $24.92 per share under a Rule 10b5-1 trading plan.

Accepted by SEC EDGAR 08/04/2026 - 03:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. EVP and Chief Legal Officer Karah Herdman Parschauer reported a sale of 1,900 shares of common stock on August 3, 2026 at $24.92 per share under a Rule 10b5-1 trading plan. Following this transaction, she directly holds 92,562 shares, including previously reported RSU-based shares subject to vesting conditions.

Insider Trade Summary 10b5-1

Net Seller: 1,900 shares

Net Sell 1 txn

Insider Parschauer Karah Herdman

Role EVP and Chief Legal Officer

Sold 1,900 shs ($47K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,900	$24.92	$47K

Holdings After Transaction: Common Stock — 92,562 shares (Direct)

Footnotes (1)

1. F1. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Key Figures

Shares sold: 1,900 shares Sale price: $24.92 per share Shares held after transaction: 92,562 shares

3 metrics

Shares sold 1,900 shares Common stock sale on August 3, 2026

Sale price $24.92 per share Consideration for the 1,900 shares sold

Shares held after transaction 92,562 shares Direct holdings following the reported sale, including RSU-based shares

Key Terms

RSUs, vesting conditions, Common Stock

3 terms

RSUs financial

"shares of common stock underlying RSUs granted to the Reporting Person"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

vesting conditions financial

"RSUs granted to the Reporting Person, which are subject to certain vesting conditions"

Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ultragenyx (RARE) report for Karah Herdman Parschauer?

Ultragenyx reported that EVP and Chief Legal Officer Karah Herdman Parschauer sold 1,900 shares of common stock on August 3, 2026 at $24.92 per share in an open-market or private transaction.

How many Ultragenyx (RARE) shares did the insider retain after the sale?

After the transaction, Karah Herdman Parschauer directly holds 92,562 shares of Ultragenyx common stock, which includes shares underlying previously reported RSUs that remain subject to vesting conditions.

Was the Ultragenyx (RARE) insider sale made under a Rule 10b5-1 plan?

Yes. The filing indicates the transaction was conducted under a Rule 10b5-1 trading plan, meaning the sale followed a pre-arranged schedule rather than being initiated at the insider’s discretion.

What price did the Ultragenyx (RARE) insider receive per share in the sale?

Karah Herdman Parschauer sold 1,900 shares of Ultragenyx common stock at a price of $24.92 per share, reflecting the per-share consideration reported for this Form 4 transaction.

Does the Ultragenyx (RARE) filing mention restricted stock units (RSUs)?

Yes. A footnote states that the 92,562 post-transaction shares include previously reported shares underlying RSUs granted to the reporting person, which are subject to vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parschauer Karah Herdman

(Last) (First) (Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

(Street)

NOVATO CALIFORNIA 94949

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		S		1,900	D	$24.92	92,562(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

	/s/ Karah Parschauer	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)